These differences inform both clinical monitoring approaches and personalized treatment strategies, including closed‐loop insulin pump systems for T1D and GLP‐1 receptor agonists (RAs) targeting postprandial fluctuations in T2D (Dandona 2017; Umpierrez and Kovatchev 2018). The gene discussed is INS; the disease is type 2 diabetes mellitus.